Amid Vertex’s continuing drug pricing battle with British regulators, the drugmaker has signed a deal to make two of its cystic fibrosis drugs available in Scotland.
Scottish regulators, grappling with covering the cost of Orkambi and Symkevi, announced last month that they would not recommend the drugs’ use. Regulators then reversed their decision on Thursday, after signing an agreement with Vertex.
Vertex declined to disclose the amount they agreed to charge in Scotland for the two drugs, citing a confidentiality clause in the agreement.
All three of Vertex’s drugs for cystic fibrosis have been approved for use in Europe, but the drugmaker has been locked in a stalemate with British regulators for several years over the 123,000 euro annual price tag (roughly $135,000 U.S.) it wants to charge for Orkambi.
Read the Boston Biz Journal coverage